Skip to main content
Equibles

CITADEL ADVISORS LLC

Position in NTLA — Intellia Therapeutics, Inc.

CIK 1423053 MIAMI, FL
Back to NTLA Full portfolio

Position in NTLA

as of Mar 31, 2026 · filed May 15, 2026
Position Value
$5,874,649
-$2,668,097 QoQ
Shares Held
458,241
-51.8% QoQ
Ownership
0.328%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2020
25 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in NTLA Over Time

Shares Held

Position Value (USD)

Derivatives in NTLA

reported options exposure · as of Mar 31, 2026
CallValue
$3,189,616
CallShares
248,800
PutValue
$5,263,892
PutShares
410,600

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Mar 31, 2026

CITADEL ADVISORS LLC holds $5,784,241,435 across 374 Biotechnology names. NTLA ranks #118 (0.1% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 INSM
INSMED Inc
 2,182,571 $356,894,009
2 ONC
BeOne Medicines Ltd.
 1,032,298 $306,561,536
3 BMRN
Biomarin Pharmaceutical Inc
 4,512,634 $254,918,694
4 JAZZ
Jazz Pharmaceuticals plc
 1,259,444 $238,097,887
5 MDGL
Madrigal Pharmaceuticals, Inc.
 453,843 $237,573,195
6 BBIO
BridgeBio Pharma, Inc.
 3,173,940 $235,696,783
7 TERN
Terns Pharmaceuticals, Inc.
 3,218,810 $169,695,662
8 PTGX
Protagonist Therapeutics, Inc
 1,551,900 $163,570,260

All Filings in NTLA

Export CSV
50 filing rows on record
Report Date Value (USD) Shares
2026-03-31 $5,874,649 458,241
2026-03-31 $5,263,892 410,600
2026-03-31 $3,189,616 248,800
2025-12-31 $3,893,569 433,100
2025-12-31 $8,542,746 950,250
2025-12-31 $6,783,854 754,600
2025-09-30 $178,830 10,355
2025-09-30 $3,169,045 183,500
2025-09-30 $6,477,977 375,100
2025-06-30 $6,659,621 709,981
2025-06-30 $2,261,518 241,100
2025-06-30 $1,752,184 186,800
2025-03-31 $19,606,308 2,757,568
2025-03-31 $725,931 102,100
2025-03-31 $1,667,295 234,500
2024-12-31 $1,370,050 117,500
2024-12-31 $29,080,855 2,494,070
2024-12-31 $3,449,028 295,800
2024-09-30 $1,216,560 59,200
2024-09-30 $2,525,595 122,900
2024-09-30 $20,332,971 989,439
2024-06-30 $2,880,306 128,700
2024-06-30 $17,068,777 762,680
2024-06-30 $2,837,784 126,800
2024-03-31 $1,953,210 71,000
2024-03-31 $2,825,277 102,700
2024-03-31 $24,505,467 890,784
2023-12-31 $5,265,623 172,700
2023-12-31 $38,395,812 1,259,292
2023-12-31 $2,271,505 74,500
2023-09-30 $3,260,022 103,100
2023-09-30 $3,370,692 106,600
2023-09-30 $62,297,186 1,970,183
2023-06-30 $5,925,334 145,300
2023-06-30 $1,517,016 37,200
2023-06-30 $65,436,729 1,604,628
2023-03-31 $43,550,516 1,168,514
2023-03-31 $1,986,491 53,300
2023-03-31 $1,390,171 37,300
2022-12-31 $2,002,686 57,400
2022-12-31 $2,686,530 77,000
2022-12-31 $41,822,118 1,198,685
2022-09-30 $5,170,704 92,400
2022-09-30 $5,260,240 94,000
2022-09-30 $31,177,218 557,134
2022-06-30 $3,892,352 75,200
2022-06-30 $20,390,230 393,938
2022-06-30 $6,847,848 132,300
2022-03-31 $6,467,630 89,000
2022-03-31 $4,382,001 60,300

Report a Problem

Category
Description
Email (optional, for follow-up)